Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study

Bone Marrow Transplantation
A GonçalvesJ-M Extra

Abstract

In spite of multimodal management including aggressive surgery and chemotherapy, the prognosis of advanced ovarian cancer (AOC) remains poor. Multicycle high-dose chemotherapy (HDC) with haematopoietic stem cell (HSC) support has been shown to be a promising procedure in various cancers including AOC. We conducted a phase II multicentre study to evaluate feasibility, toxicity and efficacy of post-operative front-line sequential HDC with HSC support in AOC. Thirty four patients with stage IIIC/IV received a post-operative sequential combination of high-dose cyclophosphamide/epirubicin (D1, D21) with HSC harvesting, high-dose carboplatin (D42, D98) followed by HSC infusion, and dose-dense paclitaxel (D63, D77, D119, D133). Rh-G-CSF (filgrastim) was administered following all cycles. Primary endpoint was pathological complete response rate (pCR). Thirty patients received at least 7 of the scheduled 8 cycles. Haematological toxicity was significant but manageable. Grade 3/4 extra-haematopoietic toxicities were relatively uncommon and reversible. No toxicity-related death was observed. The observed pCR was 37% and did not reach the initial endpoint. Post-operative front-line sequential HDC in AOC is feasible and safe in a multicentr...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P NeijtM van Lent
Apr 1, 1989·European Journal of Cancer & Clinical Oncology·P O MulderN H Mulder
May 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Levin, W M Hryniuk
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Nov 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P Benedetti-PaniciR Serafini
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LegrosR Plagne
Aug 1, 1997·Bone Marrow Transplantation·P ViensD Maraninchi
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C AghajanianD R Spriggs
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J SchilderR F Ozols
Dec 10, 1999·Critical Reviews in Oncology/hematology·P F ConteA Gadducci
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J SchilderR F Ozols
Jul 4, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A LedermannG Rosti
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E Pujade-LauraineJ P Lotz
Oct 12, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F E de JonghM E L van der Burg
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William P McGuire

❮ Previous
Next ❯

Citations

Oct 18, 2012·Journal of Experimental & Clinical Cancer Research : CR·Renaud SabatierJean-Marc Extra
May 20, 2011·Cancer Treatment Reviews·Marc DebledPierre Soubeyran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.